Identification of a critical ligand binding determinant of the human erythropoietin receptor - Evidence for common ligand binding motifs in the cytokine receptor family

被引:47
作者
Middleton, SA
Johnson, DL
Jin, RZ
McMahon, FJ
Collins, A
Tullai, J
Gruninger, RH
Jolliffe, LK
Mulcahy, LS
机构
[1] R. W. Johnson Pharmaceut. Res. Inst., Raritan
[2] R. W. Johnson Pharmaceut. Res. Inst., Raritan, NJ 08869
关键词
D O I
10.1074/jbc.271.24.14045
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains. We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding, Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays. Substitution of phenylalanine at position 93 (Phe(93)) with alanine (F93A mutation) resulted in a drastic reduction in EPO binding in the FBP. More conservative tyrosine or tryptophan substitutions at Phe(93) resulted in much less dramatic effects on EPO binding, Biophysical studies indicated that the F93A mutation does not result in gross structural alterations in the EBP, Furthermore, the F93A mutation in full-length EPOR expressed in COS cells abolished detectable EPO binding, This was not a result of processing or transport defects, since mutant receptor was present on the surface of the cells, Mutations in the region immediately around Phe(93) and in residues homologous to other reported ligand binding determinants of the cytokine receptor family had small to moderate effects on EPO binding. These data indicate that Phe(93) is a critical EPO binding determinant of the EPOR. Furthermore, since Phe(93) aligns with critical ligand binding determinants in other receptors of the cytokine receptor family, these data suggest that receptors of this family may use common structural motifs to bind their cognate ligands.
引用
收藏
页码:14045 / 14054
页数:10
相关论文
共 46 条
[21]   Refolding, purification, and characterization of human erythropoietin binding protein produced in Escherichia coli [J].
Johnson, DL ;
Middleton, SA ;
McMahon, F ;
Barbone, FP ;
Kroon, D ;
Tsao, E ;
Lee, WH ;
Mulcahy, LS ;
Jolliffe, LK .
PROTEIN EXPRESSION AND PURIFICATION, 1996, 7 (01) :104-113
[22]   ERYTHROPOIETIN RECEPTOR - APPLICATION IN DRUG DEVELOPMENT [J].
JOLLIFFE, LK ;
MIDDLETON, SA ;
BARBONE, FP ;
JOHNSON, DL ;
MCMAHON, FJ ;
LEE, WH ;
GRUNINGER, RH ;
MULCAHY, LS .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 :28-34
[23]  
JONES SS, 1990, BLOOD, V76, P31
[24]   SPECIFIC RECRUITMENT OF SH-PTP1 TO THE ERYTHROPOIETIN RECEPTOR CAUSES INACTIVATION OF JAK2 AND TERMINATION OF PROLIFERATIVE SIGNALS [J].
KLINGMULLER, U ;
LORENZ, U ;
CANTLEY, LC ;
NEEL, BG ;
LODISH, HF .
CELL, 1995, 80 (05) :729-738
[25]  
KRANTZ SB, 1991, BLOOD, V77, P419
[26]   ERYTHROPOIETIN RECEPTOR SIGNALS BOTH PROLIFERATION AND ERYTHROID-SPECIFIC DIFFERENTIATION [J].
LIBOI, E ;
CARROLL, M ;
DANDREA, AD ;
MATHEYPREVOT, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11351-11355
[27]   THE ERYTHROPOIETIN RECEPTOR - ITS ROLE IN HEMATOPOIESIS AND MYELOPROLIFERATIVE DISEASES [J].
LONGMORE, GD ;
WATOWICH, SS ;
HILTON, DJ ;
LODISH, HF .
JOURNAL OF CELL BIOLOGY, 1993, 123 (06) :1305-1308
[28]  
MASUDA S, 1993, J BIOL CHEM, V268, P11208
[29]   DIMERIZATION AND OLIGOMERIZATION OF THE ERYTHROPOIETIN RECEPTOR BY DISULFIDE BOND FORMATION AND SIGNIFICANCE OF THE REGION NEAR THE WSXWS MOTIF IN INTRACELLULAR-TRANSPORT [J].
MIURA, O ;
IHLE, JN .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 306 (01) :200-208
[30]  
MIYAKE T, 1977, J BIOL CHEM, V252, P5558